{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994070818048.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1136/gutjnl-2015-311079"}},{"identifier":{"@type":"URI","@value":"https://syndication.highwire.org/content/doi/10.1136/gutjnl-2015-311079"}}],"dc:title":[{"@value":"The safety of vedolizumab for ulcerative colitis and Crohn's disease"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                    <jats:title>Objective</jats:title>\n                    <jats:p>\n                      Vedolizumab is a gut-selective antibody to α\n                      <jats:sub>4</jats:sub>\n                      β\n                      <jats:sub>7</jats:sub>\n                      integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Design</jats:title>\n                    <jats:p>Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1–1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (≤0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor α antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ≤5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number</jats:title>\n                    <jats:p>\n                      NCT01177228,\n                      <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00619489\">NCT00619489</jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00783718\">NCT00783718</jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00783692\">NCT00783692</jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01224171\">NCT01224171</jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00790933\">NCT00790933</jats:ext-link>\n                      .\n                    </jats:p>\n                  </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994070818053","@type":"Researcher","foaf:name":[{"@value":"Jean-Frédéric Colombel"}],"jpcoar:affiliationName":[{"@value":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818048","@type":"Researcher","foaf:name":[{"@value":"Bruce E Sands"}],"jpcoar:affiliationName":[{"@value":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818049","@type":"Researcher","foaf:name":[{"@value":"Paul Rutgeerts"}],"jpcoar:affiliationName":[{"@value":"Division of Gastroenterology, Katholieke Universiteit and University Hospital Gasthuisberg, Leuven, Belgium"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818052","@type":"Researcher","foaf:name":[{"@value":"William Sandborn"}],"jpcoar:affiliationName":[{"@value":"Division of Gastroenterology, University of California San Diego and UC San Diego Health System, La Jolla, California, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818057","@type":"Researcher","foaf:name":[{"@value":"Silvio Danese"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818060","@type":"Researcher","foaf:name":[{"@value":"Geert D'Haens"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818051","@type":"Researcher","foaf:name":[{"@value":"Remo Panaccione"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818061","@type":"Researcher","foaf:name":[{"@value":"Edward V Loftus"}],"jpcoar:affiliationName":[{"@value":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818054","@type":"Researcher","foaf:name":[{"@value":"Serap Sankoh"}],"jpcoar:affiliationName":[{"@value":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818055","@type":"Researcher","foaf:name":[{"@value":"Irving Fox"}],"jpcoar:affiliationName":[{"@value":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818056","@type":"Researcher","foaf:name":[{"@value":"Asit Parikh"}],"jpcoar:affiliationName":[{"@value":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818058","@type":"Researcher","foaf:name":[{"@value":"Catherine Milch"}],"jpcoar:affiliationName":[{"@value":"Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818059","@type":"Researcher","foaf:name":[{"@value":"Brihad Abhyankar"}],"jpcoar:affiliationName":[{"@value":"Takeda Global Research and Development Centre (Europe) Ltd., London, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994070818050","@type":"Researcher","foaf:name":[{"@value":"Brian G Feagan"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00175749"},{"@type":"EISSN","@value":"14683288"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00175749"}],"prism:publicationName":[{"@value":"Gut"}],"dc:publisher":[{"@value":"BMJ"}],"prism:publicationDate":"2016-02-18","prism:volume":"66","prism:number":"5","prism:startingPage":"839","prism:endingPage":"851"},"reviewed":"false","url":[{"@id":"https://syndication.highwire.org/content/doi/10.1136/gutjnl-2015-311079"}],"createdAt":"2016-04-13","modifiedAt":"2025-09-07","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050586809213633280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142795004672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567780182784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045524540160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020"}]},{"@id":"https://cir.nii.ac.jp/crid/1390014967590267136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Concomitant <i>Clostridioides difficile</i> and<i> Edwardsiella tarda</i> Infection in a Patient with Ulcerative Colitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390569789595947136","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Leading Edge of the Treatment of Inflammatory Bowel Disease"},{"@language":"ja","@value":"炎症性腸疾患の治療の最前線"},{"@value":"医学と医療の最前線 炎症性腸疾患の治療の最前線"},{"@language":"ja-Kana","@value":"イガク ト イリョウ ノ サイゼンセン エンショウセイ チョウ シッカン ノ チリョウ ノ サイゼンセン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390577530423003136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1391975276376246528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Characteristics and management of elderly-onset ulcerative colitis"},{"@language":"ja","@value":"2．高齢発症潰瘍性大腸炎の特徴と治療"},{"@value":"高齢発症潰瘍性大腸炎の特徴と治療"},{"@language":"ja-Kana","@value":"コウレイ ハッショウ カイヨウセイ ダイチョウエン ノ トクチョウ ト チリョウ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1136/gutjnl-2015-311079"},{"@type":"CROSSREF","@value":"10.2152/jmi.70.294_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.0571-22_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.5217/ir.2024.00063_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.2169/naika.109.1145_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.1159/000510502_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.3143/geriatrics.57.414_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.5217/ir.2020.00026_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"},{"@type":"CROSSREF","@value":"10.1007/s00535-021-01784-1_references_DOI_L0gJF74hqfjkBnZ8hySXmav5tEC"}]}